Renal Denervation (RDN)

Interventional Treatment of Hypertension: From Renal Denervation to the Next Wave

by Prateek Chopra | June 20, 2026 | Cardiology Conferences | ESH 2026 Therapeutic Context: Renal denervation (RDN) is emerging as a third pillar of hypertension management, alongside lifestyle modification and pharmacotherapy, for selected patients with uncontrolled or resistant hypertension. The clinical question is whether RDN provides benefits beyond BP reduction and whether a single intervention is sufficient for BP control. […]

Interventional Treatment of Hypertension: From Renal Denervation to the Next Wave Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,

Blood Pressure Lowering Effects of Pharmacological and Device Based Interventions for Resistant Hypertension: A Systematic Review and Meta-Analysis

by Prateek Chopra | June 17, 2026 | Cardiology Conferences | ESH 2026 Clinical Context: Resistant hypertension (RHTN) remains a major clinical challenge. This systematic review and meta-analysis evaluated the blood pressure-lowering efficacy and hypertension control rates achieved after the addition of pharmacological or device-based interventions (e.g., renal denervation, RDN) in patients with true RHTN. Study Design: Key Findings: Clinical Implications:

Blood Pressure Lowering Effects of Pharmacological and Device Based Interventions for Resistant Hypertension: A Systematic Review and Meta-Analysis Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,

Redefining Hypertension Therapy in 2036: Precision, Permanence,and Prevention

by Prateek Chopra | June 5, 2026 | Cardiology Conferences | ESH 2026 Emerging Paradigm: Hypertension affects ~1.3 billion people worldwide, yet fewer than 25% achieve adequate BP control. Poor medication adherence, especially with polypharmacy, remains a critical barrier. This review explores whether hypertension therapy requires reinvention and evaluates emerging pharmacological, device-based, and AI-driven strategies poised to transform care by 2036.

Redefining Hypertension Therapy in 2036: Precision, Permanence,and Prevention Read Post »

Leave a Comment / ESH Day 1 / / / , , , ,

Renal Denervation for Resistant Hypertension in CKD and ESRD: ESH 2026 Clinical Update

by Prateek Chopra | June 4, 2026 | Cardiology Conferences | ESH 2026 Clinical Rationale: Renal denervation (RDN) is being evaluated as an adjunctive therapy for patients with advanced CKD, end-stage renal disease (ESRD), and resistant hypertension. Current evidence is drawn from ESH/ESC recommendations, sham-controlled randomized trials, registries, observational studies, and ongoing clinical protocols. Current Recommendations: Key Evidence: Emerging Applications: Renal

Renal Denervation for Resistant Hypertension in CKD and ESRD: ESH 2026 Clinical Update Read Post »

Leave a Comment / ESH Day 1 / / / , , , ,

Renal Denervation in Chronic Heart Failure: A New Era Beyond Blood Pressure Control

by Prateek Chopra | June 3, 2026 | Cardiology Conferences | ESH 2026 Treatment Rationale: Renal denervation (RDN) is an emerging interventional strategy in chronic heart failure (CHF), particularly in patients with sympathetic nervous system (SNS) overactivity. Excessive SNS activation contributes to hypertension, cardiac remodeling, fibrosis, arrhythmias, endothelial dysfunction, renal sodium retention, and progression of heart failure. Mechanism of Action: Clinical

Renal Denervation in Chronic Heart Failure: A New Era Beyond Blood Pressure Control Read Post »

Leave a Comment / ESH Day 1 / / / , , , ,
Scroll to Top